



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT

Docket Number:
2664/57104

Application Number
10/606,403

Filing Date
June 25, 2003

Examiner
To be assigned

Art Unit
1625

Invention Title
**NOVEL PROCESS FOR PREPARING AND ISOLATING
RAC-BICALUTAMIDE AND ITS INTERMEDIATES**

Inventor(s)
Ben-Zion DOLITZKY et al.

Address to
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Date: 10/6/03 Reg. No. 46,877

Signature: *Siu K. Lo*
Siu K. Lo

Sir:


1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 35 U.S.C. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the following references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. Copies of each patent, publication or other information listed on the modified PTO form 1449 are not enclosed since they were previously cited by or submitted to the Patent Office in prior application Serial No. 10/170,721 which is relied upon for an earlier filing date under 35 U.S.C. 120.
3. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge Deposit Account No. 11-0600 for such fees. A duplicate copy of this communication is enclosed for charging purposes.

Dated: 10/6/03

By: *Siu K. Lo*

Siu K. Lo (Reg. No. 46,877)

KENYON & KENYON
One Broadway
New York, N.Y. 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)



INFORMATION DISCLOSURE STATEMENT BY APPLICANT	DOCKET NO. 2664/57104	SERIAL NO 10/606,403
	APPLICANT Dolitzky et al.	
	FILING DATE June 25, 2003	GROUP 1625

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*
	4,636,505	January 13, 1987	Tucker			
	6,358,985	March 19, 2002	Anthony et al.			
	6,306,874	October 23, 2001	Fraley et al.			
	6,291,504	September 18, 2001	Nugiel et al.			
	6,184,249	February 6, 2001	Sovak et al.			
	6,160,011	December 12, 2000	Miller et al.			


FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 93/19770	October 14, 1993	PCT			x	
	WO 01/00608	January 4, 2001	PCT			x	

OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		MacPeck, Donald L. et al., "Synthesis of Glycidic Esters by Epoxidation of α,β -Unsaturated Esters with Peracetic Acid," J. Am. Chem., 1959, Vol. 81, pp. 680-683
		Emmons, William D. et al., "Peroxytrifluoroacetic Acid. IV. The Epoxidation of Olefins," J. Am. Chem., 1955, Vol. 77, pp. 89-92
		Ho, Winston et al., "Alkylglycidic Acids: Potential New Hypoglycemic Agents," J. Med. Chem., 1986, Vol. 29, pp. 2184-2190
		Lieberman, Herbert A. et al., <u>Pharmaceutical Dosage Forms: Tablets</u> , Volume 2, 2 nd Ed., Marcel Dekker, Inc., New York (1990), pp. 107-200

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



INFORMATION DISCLOSURE STATEMENT BY APPLICANT	DOCKET NO. 2664/57104	SERIAL NO 10/606,403
	APPLICANT Dolitzky et al.	
	FILING DATE June 25, 2003	GROUP 1625

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE
	4,554,381	November 19, 1985	Desbois			
	5,723,485	March 3, 1998	Gungor et al.			
	3,254,094	May 31, 1966	Ross			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		Database CAPLUS on STN, Chemical Abstracts, CA: 129:244921, Freskos et al., "Preparation of aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds as matrix metalloprotease inhibitors"
		Database CAPLUS on STN, Chemical Abstracts, CA:128:75188, Takahashi et al., "Preparation and formulation of aryl sulfides, sulfoxides, and sulfones as matrix metalloproteinase inhibitors"
		Database CAPLUS on STN, Chemical Abstracts, CA: 136:12767, Shusarek et al., "Color photographic thermally processable film comprising blocked developer compound"
		Database CAPLUS on STN, Chemical Abstracts, CA: 86:171116, Buettner et al., "Trifluoromethyl-substituted aminobenzonitriles"
		Database CAPLUS on STN, Chemical Abstracts, CA: 108:150026, Tucker et al., "Resolution of the non-steroidal antiandrogen 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl) propionanilide and the determination of the absolute configuration of the active enantiomer"
		Database CAPLUS on STN, Chemical Abstracts, CA: 2002:414656, James et al., "A two-step synthesis of the anti-cancer drug (r,S)-bicalutamide"
		Database CAPLUS on STN, Chemical Abstracts, CA:120:191513, Horschler von Locquenghien et al., "Preparation of oxiranecarboxylates and analogs"
		Database CAPLUS on STN, Chemical Abstracts, CA:89:90113, Rastetter, et al. "3,5-Dinitroperoxybenzoic acid. A crystalline, storable substitute for peroxytrifluoroacetic acid"
		Database CAPLUS on STN, Chemical Abstracts, CA:134:326279, Ekwuribe, et al. "Asymmetric synthesis and antiandrogenic use of enantiomers of Casodex (bicalutamide) and derivatives from enantiomers of citramalic acid or proline"

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	